Among adults who have both asthma and type 2 diabetes, starting tirzepatide rather than semaglutide made no difference to the chance of an asthma attack over a year. A US multicentre analysis of 16,352 matched patients, published on 7 September 2026, found that 11.0% of the tirzepatide group and 11.1% of the semaglutide group had … Read more
For most of the time this site has covered semaglutide, the scarring form of fatty liver disease had no approved drug treatment at all. That has changed. An international expert panel writing in Gut on 11 September 2026 has published a clinical practice update for the two therapies now conditionally approved by the FDA for … Read more
A meta-analysis of 60 studies and more than 1.25 million people, published in Drugs on 12 September 2026, gives the fullest picture yet of what GLP-1 drugs do to muscle, bone and joints. The bone finding is reassuring: no measurable effect on bone mineral density, and none on fractures. The muscle finding is the one … Read more
Between a quarter and a third of people who have bariatric surgery regain a significant amount of weight within two to five years, according to the figures cited by the authors of a new review. Their meta-analysis, published in Frontiers in Endocrinology, pulls together what is known about treating that regain with a GLP-1 drug … Read more
Novo Nordisk reported on 7 September that 40.4% of children aged 6 to under 12 who took once-weekly semaglutide in its STEP Young trial were no longer classified as having obesity after 68 weeks, compared with none of the children given placebo. Every child in both arms also followed a reduced-calorie diet and an exercise … Read more
Among 216,293 adults with type 2 diabetes, starting an SGLT2 inhibitor was associated with a lower five-year risk of atrial fibrillation than starting a GLP-1 receptor agonist: 4.3% against 4.8%. Starting both classes together came in at 4.2%, statistically indistinguishable from SGLT2 alone. For anyone weighing the two classes with an eye on heart rhythm … Read more
For people with type 2 diabetes who already have nerve damage in their feet, a matched comparison of 39,540 US patients found fewer foot ulcers on GLP-1 receptor agonists than on DPP-4 inhibitors — and nearly twice the rate of Charcot neuroarthropathy, a joint-destroying complication of the foot. Amputation and bone-infection rates were the same … Read more
A meta-analysis of 19 randomised trials behind semaglutide, tirzepatide and liraglutide reports a gap between what those trials recorded and what their own bloodwork showed. Investigators logged malnutrition as an adverse event in 0.12% of participants. Laboratory screening in the same trials found abnormally low lymphocyte counts in 2.90% of people taking active drug, against … Read more